

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No. 6843MRRC
First Inventor Benoit Ledoussal
Assignee The Procter & Gamble Company
Title Antimicrobial Quinolones, Their Compositions and Uses
Express Mail Label No. EJ302199110US

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO:

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total Pages [48]
(preferred arrangement set forth below)
- Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC §113) Total Sheets ☐
4. Oath or Declaration Total pages [4]
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 complete)
- i. ☐ DELETION OF INVENTORS
Signed statement attached deleting inventor(s)
named in the prior application,
see 37 CFR §§1.63(d)(2) and 1.33(b).
5. ☐ Application Data Sheet. See 37 CFR §1.76

6. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ Paper
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure ☐ Copies of IDS Statement (IDS)/PTO-1449 Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR §1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 09/929,943

Prior application information: Examiner: D. Margaret M. Seaman Group/Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number(Insert Customer No. here)
27746

Name (Print/Type)

David V. Uptie

Registration No. (Attorney/Agent)

47, 147

Signature

David V. Uptie

Date

February 28, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231

(Revised for P&G use 12/7/01)

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No.	6843MRRC
First Inventor	Benoit Ledoussal
Assignee	The Procter & Gamble Company
Title	Antimicrobial Quinolones, Their Compositions and Uses
Express Mail Label No.	EJ302199110US-7



APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: **Box Patent Application**
Assistant Commissioner for Patents
Washington, D.C. 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total Pages [48]
(preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC §113) Total Sheets ☐
4. Oath or Declaration Total Pages [4]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 complete)
 - i. ☐ **DELETION OF INVENTORS**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b).
5. ☐ Application Data Sheet. See 37 CFR §1.76

6. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ Paper
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR §1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 09/929,943
Prior application information: Examiner: D. Margaret M. Seaman Group/Art Unit: 1625
For **CONTINUATION OR DIVISIONAL APPS** only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number(Insert Customer No. here)
27746

Name (Print/Type)	David V. Upile	Registration No. (Attorney/Agent)	47, 147
Signature	<i>David V. Upile</i>	Date	February 28, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231

(Revised for P&G use 12/7/01)

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	
Confirmation Number	
Filing Date	
First Named Inventor	Benoit Ledoussal
Examiner Name	D. Margaret M. Seaman
Group/Art Unit	1625
Attorney Docket No.	6843MRRC

TOTAL AMOUNT OF PAYMENT (\$740.00)

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-2480
 Deposit Account Name The Procter & Gamble Company

- ☒ Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16 and 1.17

FEE CALCULATION

BASIC FILING FEE - Large Entity

Code (\$)	Fee Description	Fee Paid
101 740	Utility filing fee	[x]
106 330	Design filing fee	[]
108 740	Reissue filing fee	[]
114 160	Provisional filing fee	[]

SUBTOTAL (1) (\$740.00)

EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity

		Extra	Fee from	Fee
		Claims	Below	Paid
Total Claims	[] - 20** =	[] x	[]	= []

Independent Claims [] - 3** = [] x [] = []

Multiple Dependent [] = []

** or number previously paid, if greater; For Reissues, see below

Code (\$)	Fee Description
103 18	Claims in excess of 20
102 84	Independent claims in excess of 3
104 280	Multiple dependent claim, if not paid
109 84	**Reissue independent claims over original patent
110 18	**Reissue claims in excess of 20 & over original patent

SUBTOTAL (2) (\$[])

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Code (\$)	Fee Description	Fee Paid
105 130	Surcharge-late filing fee or oath	[]
127 50	Surcharge-late provisional filing fee or cover sheet	[]
139 130	Non-English specification	[]
147 2,520	For filing a request for <i>ex parte</i> reexamination	[]
112 920*	Requesting publication of SIR prior to Examiner's action	[]
113 1,840*	Requesting publication of SIR after Examiner's action	[]
115 110	Extension for reply within 1 st month	[]
116 400	Extension for reply within 2 nd month	[]
117 920	Extension for reply within 3 rd month	[]
118 1,440	Extension for reply within 4 th month	[]
128 1,960	Extension for reply within 5 th month	[]
119 320	Notice of Appeal	[]
120 320	Filing a brief in support of an appeal	[]
121 280	Request for oral hearing	[]
138 1,510	Petition to institute a public use proceeding	[]
140 110	Petition to revive - unavoidable	[]
141 1,280	Petition to revive - unintentional	[]
142 1,280	Utility issue fee (or reissue)	[]
143 460	Design issue fee	[]
122 130	Petitions to the Commissioner	[]
123 50	Petitions related to provisional applications (37 C.F.R. 1.17(q))	[]
126 180	Submission of Information Disclosure Statement	[]
146 740	Filing a submission after final rejection (37 CFR § 1.129(a))	[]
149 740	For each additional invention to be examined (37 CFR § 1.129(b))	[]
179 740	Request for Continued Examination (RCE)	[]
169 900	Request for expedited examination of a design application	[]
091 1280	Acceptance of unintentionally delayed claim for priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)	[]

Other fee (specify) _____
 Other fee (specify) _____

* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$[])

SUBMITTED BY

Name (Print/Type)	David V. Upite	Registration No.	47,147	Complete (if applicable)	
Signature	<i>David V. Upite</i>	(Attorney/Agent)		Telephone	(513) 622-1825
				Date	February 28, 2002

WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2034.
 Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.